Menu

Asbestos Mortality Rates Far Exceed National Average in Eight Texas Counties, Baron & Budd Reports

Asbestos Mortality Rates Far Exceed National Average in Eight Texas Counties, Baron & Budd Reports Environmental Working Group Analysis Shows Alarming Rate of Deaths in Beaumont, Orange and Port Arthur Areas, Dubbed "Asbestos Alley" DALLAS [...]

January 7th, 2016|Asbestos / Mesothelioma|

New EWG Interactive Map Shows State-By-State Death Tolls Due to Asbestos-Related Diseases, Baron & Budd Reports

Map Paints a Stark Picture of the Effect Asbestos Has Had in the U.S. DALLAS (Sept. 2, 2015) – An interactive map recently released by the Environmental Working Group (EWG) shows how much of [...]

September 2nd, 2015|Asbestos / Mesothelioma|

Aggressive Surgery May Help Extend Mesothelioma Patients’ Lives, Baron & Budd Reports

Procedure May Also Improve Quality of Life DALLAS (Aug. 19, 2015) – Researchers at the University of Chicago Medical Center recently released a study showing that aggressive surgical procedures tend to extend the lifespan of [...]

August 19th, 2015|Asbestos / Mesothelioma|

Clinical Trial Results Show Mesothelioma Drug Could Extend Patients’ Lives, Baron & Budd Reports

Tremelimumab May Help Body's Immune System Destroy Mesothelioma Cells While Keeping Healthy Ones Unharmed DALLAS (May 20, 2015) – Results of a clinical trial conducted by a team of Italian researchers showed a new drug [...]

May 20th, 2015|Asbestos / Mesothelioma|

Tremelimumab Receives Orphan Drug Designation from FDA for Malignant Mesothelioma Treatment, Baron & Budd Reports

Drug Attacks Malignant Cells While Leaving Nearby Healthy Cells Unharmed DALLAS (May 13, 2015) – The mesothelioma law firm of Baron & Budd reports the U.S. Food and Drug Administration (FDA) has granted orphan drug [...]

May 13th, 2015|Asbestos / Mesothelioma|

Research Study Shows Immunotherapy Drug Could Potentially Benefit Mesothelioma Patients, Baron & Budd Reports

Pembrolizumab May Shrink or Halt Spread of Tumors, According to Study Results DALLAS (May 4, 2015) – Researchers at the University of Pennsylvania recently released the results of a study showing that the cancer immunotherapy [...]

May 4th, 2015|Asbestos / Mesothelioma|

Stem Cell Trials Show Early Promise for Mesothelioma Treatment, Baron & Budd Reports

New Defactnib Drug Reportedly Shrinks Tumors DALLAS (April 28, 2015) – A clinical trial being held in multiple countries has yielded effective results in patients with mesothelioma, the mesothelioma law firm of Baron & Budd [...]

April 28th, 2015|Asbestos / Mesothelioma|

Mesothelioma Immunotherapy Vaccine Receives Orphan Drug Designation from FDA, Baron & Budd Reports

CRS-207 Drug Shows Substantial Promise in Shrinking Mesothelioma Tumors When Combined with Chemotherapy DALLAS (April 23, 2015) – The mesothelioma law firm of Baron & Budd reports the U.S. Food and Drug Administration has granted [...]

April 23rd, 2015|Asbestos / Mesothelioma|

Ingredient Found in Common Vinegar Proves Effective in Killing Mesothelioma Cells, Baron and Budd Reports

Researchers Show that Acetic Acid Could Possibly Be a Feasible Treatment DALLAS (Jan. 30, 2015) – A team of Japanese researchers recently published a study showing that the application of acetic acid – an ingredient [...]

January 30th, 2015|Asbestos / Mesothelioma|

Mesothelioma Lawyers Baron and Budd Highlight Young North Texas Woman’s Mesothelioma Diagnosis

DALLAS--(BUSINESS WIRE)--The case of a young North Texas woman diagnosed with mesothelioma highlights the risk of developing the disease through secondhand exposure to asbestos, the mesothelioma law firm of Baron and Budd reports. Mesothelioma is [...]

December 18th, 2014|Asbestos / Mesothelioma|